When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Буллезный пемфигоид

Última revisão: 13 Sep 2025
Última atualização: 11 Dec 2020

Resumo

Definição

História e exame físico

Principais fatores diagnósticos

  • наличие факторов риска
  • зуд
  • напряженные пузыри на нормальной или эритематозной коже
Detalhes completos

Outros fatores diagnósticos

  • эритематозные или уртикарные бляшки
  • поражения полости рта
Detalhes completos

Fatores de risco

  • возраст от 60 до 90 лет
  • главный комплекс гистосовместимости (ГКГС) аллели II класса (DQB1*0301)
  • мужской пол
Detalhes completos

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • биопсия кожи для гистопатологической оценки с помощью световой микроскопии
  • биопсия кожи для исследования методом прямой иммунофлюоресценции
  • исследование методом непрямой иммунофлуоресценции сыворотки
Detalhes completos

Investigações a serem consideradas

  • Анализ ELISA
Detalhes completos

Novos exames

  • иммуноблоттинг
  • иммунопреципитация
  • техника флюоресцентного наложения антигена (FOAM)

Algoritmo de tratamento

AGUDA

локализованные поражения у детей или взрослых

широко распространенные поражения у взрослых

широко распространенные поражения у детей

Colaboradores

Autores

Vesna Petronic-Rosic, MD, MSc, MBA

Professor and Chair

Department of Dermatology

Georgetown University

MedStar Washington Hospital Center

Washington

DC

Declarações

VPR declares that she has no competing interests.

Revisores

Lawrence Parish, MD

Clinical Professor of Dermatology and Cutaneous Biology

Director

Jefferson Center for International Dermatology

Jefferson Medical College

Thomas Jefferson University

Philadelphia

PA

Disclosures

LP declares that he has no competing interests.

Timothy Patton, MD

Assistant Professor of Dermatology

Department of Dermatology

University of Pittsburgh

Pittsburgh

PA

Disclosures

TP declares that he has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Cotell S, Robinson ND, Chan LS. Autoimmune blistering skin diseases. Am J Emerg Med. 2000;18:288-299. Abstract

Kirtschig G, Middleton P, Bennett C, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2010;(10):CD002292.Full text  Abstract

Kirtschig G, Khumalo NP. Management of bullous pemphigoid: recommendations for immunomodulatory treatments. Am J Clin Dermatol. 2004;5:319-26. Abstract

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Буллезный пемфигоид images
  • Differentials

    • пузырчатка обыкновенная
    • Приобретённый буллезный эпидермолиз
    • Линейный IgA-зависимый дерматоз
    More Differentials
  • Guidelines

    • Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita
    • Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita)
    More Guidelines
  • Calculators

    показатель общего состояния пациента по шкале Карновского

    More Calculators
  • padlock-lockedConectar-se ou assinar para acessar todo o BMJ Best Practice

O uso deste conteúdo está sujeito ao nosso aviso legal